A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

We thank Yutaka Shimazu for his constructive comments on our HD21 trial.1 In the PET-2 positive cohort, 165 (69%) of 240 patients treated with brentuximab vedotin, etoposide, cyclophosphamide, ...